Generic placeholder image

Current Aging Science

Editor-in-Chief

ISSN (Print): 1874-6098
ISSN (Online): 1874-6128

Research Article

An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q10 and Co-enzyme Q10 /Levodopa-carbidopa Combination in Mice

Author(s): Olakunle J. Onaolapo, Ademola O. Odeniyi, Stephen O. Jonathan, Moyinoluwa O. Samuel, Deborah Amadiegwu, Ajoke Olawale, Aisha O. Tiamiyu, Folusho O. Ojo, Hameed A. Yahaya, Oluwadamilare J. Ayeni and Adejoke Y. Onaolapo*

Volume 14, Issue 1, 2021

Published on: 23 October, 2019

Page: [62 - 75] Pages: 14

DOI: 10.2174/1874609812666191023153724

Abstract

Background: Despite decades of research, neurodegenerative disorders like Parkinson’s disease remain a leading cause of disability worldwide, due to the insufficient reduction of disease burden by available medications. Recently, the benefits of dietary supplements like co-enzyme Q10 in neurodegenerative diseases have been reported.

Aim: The protective effects of supplemental co-enzyme Q10 (CQ10) and possible additive benefits of CQ10/Levodopa-Carbidopa (LD) in Chlorpromazine (CPZ)-induced Parkinsonism-like changes in mice were investigated.

Methods: Male mice were assigned to ten groups of 30 mice each. Groups included: Vehicle control (fed Standard Diet (SD), and given intraperitoneal {ip} plus oral saline), LD group (fed SD, and given ip saline plus oral LD), two groups fed CQ10-supplemented diet (at 60 and 120 mg/kg of feed), and given ip plus oral saline, CPZ group (fed SD, and given ip CPZ plus oral saline), CPZ/LD group (fed SD, and given ip CPZ plus oral LD), two groups fed CQ10-supplemented diet (at 60 and 120 mg/kg of feed) and given ip CPZ plus oral saline, and another two groups fed CQ10-supplemented diet (at 60 and 120 mg/kg of feed) and given ip CPZ plus oral LD. The total duration of study was 21 days, and treatments were administered daily. Bodyweight and food intake were measured weekly, while neurobehavioural and biochemical tests were assessed at the end of the experimental period.

Results: CQ10-supplementation was protective against CPZ-induced parkinsonism-like changes including, reduction in mortality, the reversal of retardation of open-field behaviours and reduction of catalepsy, increase in dopamine levels and decreased oxidative stress. CQ10 also showed significant improvements in these parameters when co-administered with LD. CQ10 (in groups administered CPZ/CQ10 60) showed greater benefit over LD on anxiety-related behaviours and also had additive benefits on working-memory.

Conclusion: Dietary CQ10-supplementation was associated with demonstrable benefits in CPZinduced Parkinsonism-like changes in mice.

Keywords: Antioxidant, dopamine, electron transfer chain, neurobehaviour, Parkinson's disease, intraperitoneal.

Graphical Abstract
[1]
Feigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abera SF, et al. Global, regional, and national burden of neurological disorders during 1990-2015: A systematic analysis for the global burden of disease study 2015. Lancet Neurol 2017; 16(11): 877-97.
[http://dx.doi.org/10.1016/S1474-4422(17)30299-5] [PMID: 28931491]
[2]
Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson's disease, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018; 11; 17(11): 939-53.
[http://dx.doi.org/10.1016/S1474-4422(18)30295-3] [PMID: 30287051]
[3]
Beitz JM. Parkinson’s disease: a review. Front Biosci 2014; 6: 65-74.
[http://dx.doi.org/10.2741/S415] [PMID: 24389262]
[4]
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of parkinson’s disease: A systematic review and meta-analysis. Neuroepidemiol 2016; 46(4): 292-300.
[http://dx.doi.org/10.1159/000445751] [PMID: 27105081]
[5]
Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord 1998; 4(2): 53-7.
[http://dx.doi.org/10.1016/S1353-8020(98)00012-1] [PMID: 18591088]
[6]
Rodrigues Silva AM, Geldsetzer F, Holdorff B, et al. Who was the man who discovered the “Lewy bodies”? Mov Disord 2010; 25(12): 1765-73.
[http://dx.doi.org/10.1002/mds.22956] [PMID: 20669275]
[7]
Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson’s disease. Subcell Biochem 2012; 65: 389-455.
[http://dx.doi.org/10.1007/978-94-007-5416-4_16] [PMID: 23225012]
[8]
Blesa J, Przedborski S. Parkinson’s disease: Animal models and dopaminergic cell vulnerability. Front Neuroanat 2014; 8: 155.
[http://dx.doi.org/10.3389/fnana.2014.00155] [PMID: 25565980]
[9]
Blandini F, Armentero MT. Animal models of Parkinson’s disease. FEBS J 2012; 279(7): 1156-66.
[http://dx.doi.org/10.1111/j.1742-4658.2012.08491.x] [PMID: 22251459]
[10]
Gubellini P, Kachidian P. Animal models of Parkinson’s disease: An updated overview. Rev Neurol (Paris) 2015; 171(11): 750-61.
[http://dx.doi.org/10.1016/j.neurol.2015.07.011] [PMID: 26343921]
[11]
Porras G, Li Q, Bezard E. Modeling Parkinson’s disease in primates: The MPTP model. Cold Spring Harb Perspect Med 2012; 2(3), a009308.
[http://dx.doi.org/10.1101/cshperspect.a009308] [PMID: 22393538]
[12]
Przedborski S, Levivier M, Jiang H, et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995; 67(3): 631-47.
[http://dx.doi.org/10.1016/0306-4522(95)00066-R] [PMID: 7675192]
[13]
Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis 2009; 34(2): 279-90.
[http://dx.doi.org/10.1016/j.nbd.2009.01.016] [PMID: 19385059]
[14]
Morrow BA, Roth RH, Redmond DE, Elsworth JD. Impact of methamphetamine on dopamine neurons in primates is dependent on age: Implications for development of Parkinson’s disease. Neuroscience 2011; 189: 277-85.
[http://dx.doi.org/10.1016/j.neuroscience.2011.05.046] [PMID: 21640165]
[15]
Mohajjel Nayebi AA, Sheidaei H. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT(1A) recaptors. Daru 2010; 18(1): 41-5.
[PMID: 22615592]
[16]
Bais S, Gill NS, Kumar N. Neuroprotective effect of juniperus communis on chlorpromazine induced parkinson disease in animal model. Zhongguo Shengwuzhipinxue Zazhi 2015., 2015542542.
[http://dx.doi.org/10.1155/2015/542542]
[17]
Khatoon H, Najam R, Mirza T, Sikandar B. Beneficial anti-Parkinson effects of camel milk in chlorpromazineinduced animal model: Behavioural and histopathological study. Pak J Pharm Sci 2016; 29(5): 1525-9.
[PMID: 27731807]
[18]
Riaz B, Ikram R, Sikandar B. Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease. Pak J Pharm Sci 2018; 31(2): 393-7.
[PMID: 29618426]
[19]
Guidelines NICE. National Institute for Health and Care Excellence 2017. Available from: www.nice.org.uk/guidance/ng71
[20]
Parkinson Society Canada Parkinson’s disease. 2014. Available from: www.parkinson.ca/site/c.kgLNIWODKpF/b.5184 077/k.CDD1/What_is Parkinsons.htm
[21]
Patel T, Chang F. Parkinson’s disease guidelines for pharmacists. Can Pharm J 2014; 147(3): 161-70.
[http://dx.doi.org/10.1177/1715163514529740] [PMID: 24847369]
[22]
Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson’s disease. CMAJ 2003; 168(3): 293-301.
[PMID: 12566335]
[23]
Pandey S, Srivanitchapoom P. Levodopa-induced dyskinesia: Clinical features, pathophysiology, and medical management. Ann Indian Acad Neurol 2017; 20(3): 190-8.
[PMID: 28904447]
[24]
Pham DQ, Plakogiannis R. Vitamin E supplementation in alzheimer’s disease, Parkinson’s disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother 2005; 39(12): 2065-72.
[http://dx.doi.org/10.1345/aph.1G271] [PMID: 16288072]
[25]
Weber CA, Ernst ME. Antioxidants, supplements, and Parkinson’s disease. Ann Pharmacother 2006; 40(5): 935-8.
[http://dx.doi.org/10.1345/aph.1G551] [PMID: 16622156]
[26]
Okubo H, Miyake Y, Sasaki S, et al. Dietary patterns and risk of Parkinson’s disease: A case-control study in Japan. Eur J Neurol 2012; 19(5): 681-8.
[http://dx.doi.org/10.1111/j.1468-1331.2011.03600.x] [PMID: 22136555]
[27]
Cassani E, Barichella M, Ferri V, et al. Dietary habits in Parkinson’s disease: Adherence to mediterranean diet. Parkinsonism Relat Disord 2017; 42: 40-6.
[http://dx.doi.org/10.1016/j.parkreldis.2017.06.007] [PMID: 28647435]
[28]
Agarwal P, Wang Y, Buchman AS, Holland TM, Bennett DA, Morris MC. MIND diet associated with reduced incidence and delayed progression of parkinsonisma in old age. J Nutr Health Aging 2018; 22(10): 1211-5.
[http://dx.doi.org/10.1007/s12603-018-1094-5] [PMID: 30498828]
[29]
Abdin AA, Hamouda HE. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism. Neuropharmacol 2008; 55(8): 1340-6.
[http://dx.doi.org/10.1016/j.neuropharm.2008.08.033] [PMID: 18817789]
[30]
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 2002; 59(10): 1541-50.
[http://dx.doi.org/10.1001/archneur.59.10.1541] [PMID: 12374491]
[31]
Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003; 10(19): 1917-21.
[http://dx.doi.org/10.2174/0929867033456882] [PMID: 12871093]
[32]
Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 2009; 5: 597-610.
[http://dx.doi.org/10.2147/NDT.S5212] [PMID: 19966907]
[33]
Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord 2010; 25(11): 1670-4.
[http://dx.doi.org/10.1002/mds.23148] [PMID: 20568096]
[34]
Beal MF, Oakes D, Shoulson I, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol 2014; 71(5): 543-52.
[http://dx.doi.org/10.1001/jamaneurol.2014.131] [PMID: 24664227]
[35]
Zhu ZG, Sun MX, Zhang WL, Wang WW, Jin YM, Xie CL. The efficacy and safety of coenzyme Q10 in Parkinson’s disease: A meta-analysis of randomized controlled trials. Neurol Sci 2017; 38(2): 215-24.
[http://dx.doi.org/10.1007/s10072-016-2757-9] [PMID: 27830343]
[36]
Onaolapo AY, Onaolapo OJ, Nwoha PU. Methyl aspartylphenylalanine, the pons and cerebellum in mice: An evaluation of motor, morphological, biochemical, immunohistochemical and apoptotic effects. J Chem Neuroanat 2017; 86: 67-77.
[http://dx.doi.org/10.1016/j.jchemneu.2017.09.001] [PMID: 28890110]
[37]
Onaolapo OJ, Ayanwale T, Agoi O, Adetimehin C, Onaolapo AY. zinc tempers haloperidol-induced behavioural changes in healthy mice. Int J Neurosci Behav Sci 2016; 4: 21-31.
[38]
Onaolapo OJ, Onaolapo AY, Akanmu MA, Olayiwola G. Caffeine/sleep-deprivation interaction in mice produces complex memory effects. Ann Neurosci 2015; 22(3): 139-49.
[http://dx.doi.org/10.5214/ans.0972.7531.220304] [PMID: 26130922]
[39]
Onaolapo OJ, Onaolapo AY, Akanmu MA, Olayiwola G. Changes in spontaneous working-memory, memory-recall and approach-avoidance following “low dose” monosodium glutamate in mice. AIMS Neurosci 2016; 3: 317-37.
[http://dx.doi.org/10.3934/Neuroscience.2016.3.317]
[40]
Onaolapo AY, Odetunde I, Akintola AS, et al. Dietary composition modulates impact of food-added monosodium glutamate on behaviour, metabolic status and cerebral cortical morphology in mice. Biomed Pharmacother 2019; 109: 417-28.
[http://dx.doi.org/10.1016/j.biopha.2018.10.172] [PMID: 30399577]
[41]
Onaolapo OJ, Aremu OS, Onaolapo AY. Monosodium glutamate-associated alterations in open field, anxiety-related and conditioned place preference behaviours in mice. Naunyn Schmiedebergs Arch Pharmacol 2017; 390(7): 677-89.
[http://dx.doi.org/10.1007/s00210-017-1371-6] [PMID: 28357464]
[42]
Onaolapo OJ, Adekola MA, Azeez TO, Salami K, Onaolapo AY. l-Methionine and silymarin: A comparison of prophylactic protective capabilities in acetaminophen-induced injuries of the liver, kidney and cerebral cortex. Biomed Pharmacother 2017; 85: 323-33.
[http://dx.doi.org/10.1016/j.biopha.2016.11.033] [PMID: 27889232]
[43]
Fink-Jensen A, Schmidt LS, Dencker D, et al. Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. Eur J Pharmacol 2011; 656(1-3): 39-44.
[http://dx.doi.org/10.1016/j.ejphar.2011.01.018] [PMID: 21269601]
[44]
Onaolapo AY, Ayeni OJ, Ogundeji MO, Ajao A, Onaolapo OJ, Owolabi AR. Subchronic ketamine alters behaviour, metabolic indices and brain morphology in adolescent rats: Involvement of oxidative stress, glutamate toxicity and caspase-3-mediated apoptosis. J Chem Neuroanat 2019; 96: 22-33.
[http://dx.doi.org/10.1016/j.jchemneu.2018.12.002] [PMID: 30529750]
[45]
Onaolapo AY, Onaolapo OJ. Nevirapine mitigates monosodium glutamate induced neurotoxicity and oxidative stress changes in prepubertal mice. Ann Med Res 2018; 25: 518-24.
[http://dx.doi.org/10.5455/annalsmedres.2018.06.118]
[46]
Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013; 42(3): 545-63.
[http://dx.doi.org/10.1016/j.ecl.2013.05.006] [PMID: 24011886]
[47]
Saini R. Coenzyme Q10: The essential nutrient. J Pharm Bioallied Sci 2011; 3(3): 466-7.
[http://dx.doi.org/10.4103/0975-7406.84471] [PMID: 21966175]
[48]
Xu Z, Huo J, Ding X, et al. Coenzyme q10 improves lipid metabolism and ameliorates obesity by regulating camkii-mediated pde4 inhibition. Sci Rep 2017; 7(1): 8253.
[http://dx.doi.org/10.1038/s41598-017-08899-7] [PMID: 28811612]
[49]
Hely MA, Morris JGL, Traficante R, Reid WGJ, O’Sullivan DJ, Williamson PM. The sydney multicentre study of Parkinson’s disease: Progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67(3): 300-7.
[http://dx.doi.org/10.1136/jnnp.67.3.300] [PMID: 10449550]
[50]
Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 2014; 29(13): 1615-22.
[http://dx.doi.org/10.1002/mds.25898] [PMID: 24821648]
[51]
Scorza FA, do Carmo AC, Fiorini AC, et al. Sudden unexpected death in Parkinson’s disease (SUDPAR): A review of publications since the decade of the brain. Clinics (São Paulo) 2017; 72(11): 649-51.
[http://dx.doi.org/10.6061/clinics/2017(11)01] [PMID: 29236909]
[52]
Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol 1997; 54(3): 260-4.
[http://dx.doi.org/10.1001/archneur.1997.00550150024011] [PMID: 9074394]
[53]
Motohashi N, Gallagher R, Anuradha V, Gollapudi R. Co-enzyme Q10 (Ubiquinone): Its implication in improving the life style of the elderly. Med Clin Rev 2017; 3: 10.
[http://dx.doi.org/10.21767/2471-299X.1000052]
[54]
Alehagen U, Aaseth J, Alexander J, Johansson P. Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly. PLoS One 2018; 13(4), e0193120.
[http://dx.doi.org/10.1371/journal.pone.0193120] [PMID: 29641571]
[55]
Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: A randomized double-blind trial. JACC Heart Fail 2014; 2(6): 641-9.
[http://dx.doi.org/10.1016/j.jchf.2014.06.008] [PMID: 25282031]
[56]
López-Lluch G, Rodríguez-Aguilera JC, Santos-Ocaña C, Navas P. Is coenzyme Q a key factor in aging? Mech Ageing Dev 2010; 131(4): 225-35.
[http://dx.doi.org/10.1016/j.mad.2010.02.003] [PMID: 20193705]
[57]
Schmelzer C, Kubo H, Mori M, et al. Supplementation with the reduced form of Coenzyme Q10 decelerates phenotypic characteristics of senescence and induces a peroxisome proliferator-activated receptor-alpha gene expression signature in SAMP1 mice. Mol Nutr Food Res 2010; 54(6): 805-15.
[http://dx.doi.org/10.1002/mnfr.200900155] [PMID: 19960455]
[58]
Tian G, Sawashita J, Kubo H, et al. Ubiquinol-10 supplementation activates mitochondria functions to decelerate senescence in senescence-accelerated mice. Antioxid Redox Signal 2014; 20(16): 2606-20.
[http://dx.doi.org/10.1089/ars.2013.5406] [PMID: 24124769]
[59]
Huo J, Xu Z, Hosoe K, et al. Coenzyme q10 prevents senescence and dysfunction caused by oxidative stress in vascular endothelial cells. Oxid Med Cell Longev 2018., 20183181759.
[http://dx.doi.org/10.1155/2018/3181759] [PMID: 30116476]
[60]
Duty S, Jenner P. Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011; 164(4): 1357-91.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01426.x] [PMID: 21486284]
[61]
Suzuki H, Gen K, Inoue Y. Comparison of the anti-dopamine D2 and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. J Psychopharmacol (Oxford) 2013; 27(4): 396-400.
[http://dx.doi.org/10.1177/0269881113478281] [PMID: 23427194]
[62]
Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998; 95(15): 8892-7.
[http://dx.doi.org/10.1073/pnas.95.15.8892] [PMID: 9671775]
[63]
Cleren C, Yang L, Lorenzo B, et al. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 2008; 104(6): 1613-21.
[http://dx.doi.org/10.1111/j.1471-4159.2007.05097.x] [PMID: 17973981]
[64]
Quigley N, Morgan D, Idzikowski C, King DJ. The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers. J Psychopharmacol (Oxford) 1996; 10(2): 146-52.
[http://dx.doi.org/10.1177/026988119601000210] [PMID: 22302892]
[65]
McCartan D, Bell R, Green JF, et al. The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. J Psychopharmacol (Oxford) 2001; 15(2): 96-104.
[http://dx.doi.org/10.1177/026988110101500211] [PMID: 11448094]
[66]
Barrett SL, Bell R, Watson D, King DJ. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol (Oxford) 2004; 18(2): 156-72.
[http://dx.doi.org/10.1177/0269881104042614] [PMID: 15260903]
[67]
Terry AV Jr, Warner SE, Vandenhuerk L, et al. Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 2008; 156(4): 1005-16.
[http://dx.doi.org/10.1016/j.neuroscience.2008.08.030] [PMID: 18801413]
[68]
Mohr E, Fabbrini G, Williams J, et al. Dopamine and memory function in Parkinson’s disease. Mov Disord 1989; 4(2): 113-20.
[http://dx.doi.org/10.1002/mds.870040202] [PMID: 2543918]
[69]
Foster PS, Drago V, Yung RC, et al. Anxiety affects working memory only in left hemibody onset Parkinson disease patients. Cogn Behav Neurol 2010; 23(1): 14-8.
[http://dx.doi.org/10.1097/WNN.0b013e3181cc8be9] [PMID: 20299858]
[70]
Foster PS, Drago V, Crucian GP, et al. Verbal and visuospatial memory in lateral onset Parkinson disease: Time is of the essence. Cogn Behav Neurol 2010; 23(1): 19-25.
[http://dx.doi.org/10.1097/WNN.0b013e3181c20de7] [PMID: 20299859]
[71]
Foster PS, Yung RC, Drago V, Crucian GP, Heilman KM. Working memory in Parkinson’s disease: The effects of depression and side of onset of motor symptoms. Neuropsychol 2013; 27(3): 303-13.
[http://dx.doi.org/10.1037/a0032265] [PMID: 23688212]
[72]
Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson’s disease: A community-based, prospective study. Neurol 2001; 56(6): 730-6.
[http://dx.doi.org/10.1212/WNL.56.6.730] [PMID: 11274306]
[73]
Molloy SA, Rowan EN, O’Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77(12): 1323-8.
[http://dx.doi.org/10.1136/jnnp.2006.098079] [PMID: 16952917]
[74]
Fernández-Ruiz J, Doudet D, Aigner TG. Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys. Psychopharmacol 1999; 147(1): 104-7.
[http://dx.doi.org/10.1007/s002130051148] [PMID: 10591875]
[75]
Costa A, Peppe A, Mazzù I, Longarzo M, Caltagirone C, Carlesimo GA. Dopamine treatment and cognitive functioning in individuals with Parkinson’s disease: The “cognitive flexibility” hypothesis seems to work. Behav Neurol 2014., 2014260896.
[http://dx.doi.org/10.1155/2014/260896] [PMID: 24825952]
[76]
Floel A, Garraux G, Xu B, et al. Levodopa increases memory encoding and dopamine release in the striatum in the elderly. Neurobiol Aging 2008; 29(2): 267-79.
[http://dx.doi.org/10.1016/j.neurobiolaging.2006.10.009] [PMID: 17098331]
[77]
Ambrée O, Richter H, Sachser N, et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer’s disease. Neurobiol Aging 2009; 30(8): 1192-204.
[http://dx.doi.org/10.1016/j.neurobiolaging.2007.11.010] [PMID: 18079024]
[78]
Monsef A, Shahidi S, Komaki A. Influence of chronic coenzyme q10 supplementation on cognitive function, learning and memory in healthy and diabetic middle aged rats. Neuropsychobiology 2019; 77(2): 92-100.
[http://dx.doi.org/10.1159/000495520] [PMID: 30580330]
[79]
Richard IH, Frank S, McDermott MP, et al. The ups and downs of Parkinson disease: A prospective study of mood and anxiety fluctuations. Cogn Behav Neurol 2004; 17(4): 201-7.
[PMID: 15622015]
[80]
Borah A, Mohanakumar KP. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007; 27(8): 985-96.
[http://dx.doi.org/10.1007/s10571-007-9213-6] [PMID: 17934805]
[81]
Skow KL, Angoa-Perez JM, Kuhn DM, Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson’s disease: consequences of L-DOPA treatment. Neurosci Biobehav Rev 35(3): 556-64.
[82]
Aboul-Fotouh S. Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol Biochem Behav 2013; 104: 105-12.
[http://dx.doi.org/10.1016/j.pbb.2012.12.027] [PMID: 23313551]
[83]
Forester BP, Harper DG, Georgakas J, Ravichandran C, Madurai N, Cohen BM. Antidepressant effects of open label treatment with coenzyme Q10 in geriatric bipolar depression. J Clin Psychopharmacol 2015; 35(3): 338-40.
[http://dx.doi.org/10.1097/JCP.0000000000000326] [PMID: 25874916]
[84]
Kabel AM, El Kholy SS. Effect of ubiquinone and resveratrol on experimentally induced parkinsonism. J Res Dev 2013; 1: 3.
[85]
Thanh HN, Minh PT, Duc LV, Thanh TB. Protective effect of coenzyme q10 on methamphetamine-induced neurotoxicity in the mouse brain. Trends in Med. Res 2016; 11: 1-10.
[http://dx.doi.org/10.3923/tmr.2016.1.10]
[86]
Mytilineou C, Walker RH. JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003; 304(2): 792-800.
[http://dx.doi.org/10.1124/jpet.102.042267] [PMID: 12538835]
[87]
Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B. Levodopa-induced plasticity: A double-edged sword in Parkinson’s disease? Philos Trans R Soc Lond B Biol Sci 2015.370(1672)20140184
[http://dx.doi.org/10.1098/rstb.2014.0184] [PMID: 26009763]

© 2022 Bentham Science Publishers | Privacy Policy